As previously disclosed, there were statistically significant increases in non-fatal serious adverse events observed in patients taking TREDAPTIVE plus statin therapy compared to patients taking placebo plus statin therapy. These events included: diabetic complications, new onset diabetes, infection, gastrointestinal, musculoskeletal, bleeding (including gastrointestinal and intracranial) and skin. There was also a small excess in heart failure.“Merck has a long and proud history of supporting major outcomes studies to investigate challenging scientific questions and advance our collective understanding of cardiovascular medicine,” said Michael Mendelsohn, M.D., senior vice president, cardiovascular medicine, Merck Research Laboratories. “The results of HPS2-THRIVE add substantially to the body of scientific knowledge in this important therapeutic area.”
Results From HPS2-THRIVE Study Of TREDAPTIVE™ (extended-release Niacin/laropiprant) Presented At American College Of Cardiology Scientific Sessions
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.